Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > August 18, 2022
Daily News
August 18, 2022
- Forxiga Replaces Januvia as Japan’s No. 1 Diabetes Drug in April-June: IQVIA
August 18, 2022
- Incyte Japan Urges Reward for Innovation in Rare Diseases as Pemazyre Filed for Ultra Orphan Cancer
August 18, 2022
- Solasia, Nippon Kayaku to Launch PTCL Drug Darvias on Aug. 22
August 18, 2022
- Japanese Society of Formulary to Support Regional Initiatives: President
August 18, 2022
- Enhertu Smashes Primary Goal in PIII for HER2 Positive Metastatic Breast Cancer
August 18, 2022
- New Panel on Drug Distribution and Pricing Likely to Launch on Aug. 31
August 18, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…